0001012895-01-500132.txt : 20011009
0001012895-01-500132.hdr.sgml : 20011009
ACCESSION NUMBER: 0001012895-01-500132
CONFORMED SUBMISSION TYPE: NT 10-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20010630
FILED AS OF DATE: 20011001
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOTECHNOLOGY CORP
CENTRAL INDEX KEY: 0000789097
STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770]
IRS NUMBER: 841016435
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: NT 10-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24641
FILM NUMBER: 1749341
BUSINESS ADDRESS:
STREET 1: 1661 LAKEVIEW CIRCLE
CITY: OGDEN
STATE: UT
ZIP: 84403
BUSINESS PHONE: 8013993632
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOTECHNOLOGY LABORATORIES INC
DATE OF NAME CHANGE: 19900503
FORMER COMPANY:
FORMER CONFORMED NAME: LJC CORP
DATE OF NAME CHANGE: 19891025
NT 10-K
1
nt10ksb.txt
LATE NOTICE 6/30/01 10KSB
1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One)
[X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR
For Period Ended: June 30, 2001
SEC FILE NUMBER: 0-24641
CUSIP NUMBER: 45253M 20 9
PART I - REGISTRANT INFORMATION
Full Name of Registrant: Immunotechnology Corporation
Address of Principal Executive Offices: 1661 Lakeview Circle, Ogden, UT 84403
PART II - Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box is appropriate)
[x] The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
NSAR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
Certain aspects of the registrant's review process have not been completed
prior to the filing date.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
David Knudson (801) 399-3632
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities and Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months (or for such shorter) period that
the registrant was required to filed such report(s) been filed? If answer is
no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by
the earnings statement to be included in the subject report or portion
thereof? [ ] Yes [X] No
2
If so, attach an explanation of the anticipated significant change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
IMMUNOTECHNOLOGY CORPORATION
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunder duly authorized.
Date: October 1, 2001.
By: /S/ David Knudson, Secretary/Treasurer